Hormones and Biomarkers Predicting Stroke in Women

预测女性中风的激素和生物标志物

基本信息

项目摘要

DESCRIPTION: (provided by applicant) The Women's Health Initiative clinical trial of estrogen plus progestin for the prevention of cardiovascular disease in healthy, postmenopausal women, which was recently stopped due to adverse effects, as well as other secondary prevention clinical trials, have found increased risk of stroke in users of estrogen plus progestin. We wish to investigate possible mechanisms for such an increase by studying biomarkers of hemostasis /inflammation as risk factors for ischemic stroke and as mediators of stroke related effects of hormone replacement therapy and other risk factors, including hypertension and lifestyle variables. The goal of the proposed study is to determine whether blood-based biomarkers related to systemic inflammation, and/or atherothrombosis/hemostasis/coagulation may be important risk factors for ischemic stroke and subtypes of ischemic stroke among older women. We will conduct a population based nested case-control study of 1050 ischemic stroke cases and 1050 matched controls among participants in the Observational Study component of the Women's Health Initiative (WHI-OS). The WHI-OS, conducted in a multi-ethnic cohort in 40 centers throughout the United States, is a prospective study of 93,676 postmenopausal women, followed for 8 to 12 years, with extensive baseline and follow-up data including blood and DNA specimens collected and stored at baseline. Multivariate modeling techniques will be used to investigate the associations of selected biomarkers, hypertension, hormone use and lifestyle variables, with risk of ischemic stroke and specific stroke subtypes as classified by central adjudicators. We will also determine whether the effects on stroke risk of established risk factors (hypertension, smoking, diabetes) and use of specific medications (statins, aspirin, non-steroidal anti-inflammatory agents, estrogen and progesterone) will be modified in the presence of markers of inflammation and/or of atherothrombosis/hemostasis.
描述:(由申请人提供)妇女健康倡议的雌激素加孕激素用于预防健康绝经后妇女心血管疾病的临床试验最近因不良反应而停止,以及其他二级预防临床试验发现,雌激素加孕激素使用者中风的风险增加。我们希望通过研究止血/炎症的生物标志物作为缺血性中风的危险因素以及作为激素替代疗法和其他危险因素(包括高血压和生活方式变量)的中风相关效应的介质,来研究这种增加的可能机制。拟议研究的目的是确定与全身炎症和/或动脉粥样硬化血栓形成/止血/凝血相关的血液生物标志物是否可能是老年女性缺血性中风和缺血性中风亚型的重要危险因素。我们将对妇女健康倡议 (WHI-OS) 观察研究部分的参与者中的 1050 例缺血性中风病例和 1050 例匹配对照进行基于人群的巢式病例对照研究。 WHI-OS 在美国 40 个中心的多种族队列中进行,是一项对 93,676 名绝经后妇女进行的前瞻性研究,随访时间为 8 至 12 年,具有广泛的基线和随访数据,包括在基线时收集和存储的血液和 DNA 样本。多变量建模技术将用于研究选定的生物标志物、高血压、激素使用和生活方式变量与缺血性中风风险和中央裁判员分类的特定中风亚型的关联。我们还将确定已确定的危险因素(高血压、吸烟、糖尿病)和特定药物(他汀类药物、阿司匹林、非甾体类抗炎药、雌激素和黄体酮)的使用对中风风险的影响是否会在炎症和/或动脉粥样硬化血栓形成/止血标志物存在的情况下发生改变。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease: the Women's Health Initiative Observational Study.
患有稳定心血管疾病的绝经后妇女的阿司匹林使用、剂量和临床结果:妇女健康倡议观察研究。
  • DOI:
    10.1161/circoutcomes.108.791269
  • 发表时间:
    2009
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Berger,JeffreyS;Brown,DavidL;Burke,GregoryL;Oberman,Albert;Kostis,JohnB;Langer,RobertD;Wong,NathanD;Wassertheil-Smoller,Sylvia
  • 通讯作者:
    Wassertheil-Smoller,Sylvia
Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the Women's Health Initiative Observational Study.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sylvia Wassertheil-Smoller其他文献

Sylvia Wassertheil-Smoller的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sylvia Wassertheil-Smoller', 18)}}的其他基金

Hormones and Biomarkers Predicting Stroke in Women
预测女性中风的激素和生物标志物
  • 批准号:
    6783439
  • 财政年份:
    2003
  • 资助金额:
    $ 58.56万
  • 项目类别:
Hormones and Biomarkers Predicting Stroke in Women
预测女性中风的激素和生物标志物
  • 批准号:
    6682487
  • 财政年份:
    2003
  • 资助金额:
    $ 58.56万
  • 项目类别:
CLIN CTR CLIN TRIAL/OBSERVATIONAL STUDY OF WHI
CLIN CTR WHI 临床试验/观察研究
  • 批准号:
    2326739
  • 财政年份:
    1994
  • 资助金额:
    $ 58.56万
  • 项目类别:
CLIN CTR CLIN TRIAL/OBSERVATIONAL STUDY OF WHI
CLIN CTR WHI 临床试验/观察研究
  • 批准号:
    6347055
  • 财政年份:
    1994
  • 资助金额:
    $ 58.56万
  • 项目类别:
CLIN CTR CLIN TRIAL/OBSERVATIONAL STUDY OF WHI
CLIN CTR WHI 临床试验/观察研究
  • 批准号:
    2326743
  • 财政年份:
    1994
  • 资助金额:
    $ 58.56万
  • 项目类别:
CLIN CTR CLIN TRIAL/OBSERVATIONAL STUDY OF WHI
CLIN CTR WHI 临床试验/观察研究
  • 批准号:
    2870476
  • 财政年份:
    1994
  • 资助金额:
    $ 58.56万
  • 项目类别:
CLIN CTR CLIN TRIAL/OBSERVATIONAL STUDY OF WHI
CLIN CTR WHI 临床试验/观察研究
  • 批准号:
    2417365
  • 财政年份:
    1994
  • 资助金额:
    $ 58.56万
  • 项目类别:
CLIN CTR CLIN TRIAL/OBSERVATIONAL STUDY OF WHI
CLIN CTR WHI 临床试验/观察研究
  • 批准号:
    6080665
  • 财政年份:
    1994
  • 资助金额:
    $ 58.56万
  • 项目类别:
CLIN CTR CLIN TRIAL/OBSERVATIONAL STUDY OF WHI
CLIN CTR WHI 临床试验/观察研究
  • 批准号:
    6370277
  • 财政年份:
    1994
  • 资助金额:
    $ 58.56万
  • 项目类别:
CLIN CTR CLIN TRIAL/OBSERVATIONAL STUDY OF WHI
CLIN CTR WHI 临床试验/观察研究
  • 批准号:
    6196731
  • 财政年份:
    1994
  • 资助金额:
    $ 58.56万
  • 项目类别:

相似海外基金

Novel mechanisms linking blood coagulation to liver fibrosis
将凝血与肝纤维化联系起来的新机制
  • 批准号:
    10722686
  • 财政年份:
    2023
  • 资助金额:
    $ 58.56万
  • 项目类别:
Lipid peroxidation- and pyroptosis-induced tissue factor activation in pathogen-induced blood coagulation
病原体诱导的血液凝固中脂质过氧化和焦亡诱导的组织因子激活
  • 批准号:
    10571353
  • 财政年份:
    2023
  • 资助金额:
    $ 58.56万
  • 项目类别:
Elucidation of changes in electrical properties during the blood coagulation process and its use for measurement of blood coagulation status during extracorporeal circulation
阐明血液凝固过程中电特性的变化及其在体外循环期间血液凝固状态测量中的应用
  • 批准号:
    23K08266
  • 财政年份:
    2023
  • 资助金额:
    $ 58.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SBIR Phase II: Innovative Platform for Low Volume Blood Coagulation Analysis
SBIR II 期:低容量凝血分析的创新平台
  • 批准号:
    2134020
  • 财政年份:
    2022
  • 资助金额:
    $ 58.56万
  • 项目类别:
    Cooperative Agreement
Construction of a multilayered network to represent blood coagulation process
构建代表血液凝固过程的多层网络
  • 批准号:
    22K12252
  • 财政年份:
    2022
  • 资助金额:
    $ 58.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Protein S Regulates Blood Coagulation by Inhibiting Factor IXa
Protein S 通过抑制 IXa 因子调节凝血
  • 批准号:
    10616732
  • 财政年份:
    2022
  • 资助金额:
    $ 58.56万
  • 项目类别:
Development of thrombus prevention technology for ECMO devices based on the blood coagulation mechanism caused by viral infections
基于病毒感染凝血机制的ECMO装置血栓预防技术开发
  • 批准号:
    21K08817
  • 财政年份:
    2021
  • 资助金额:
    $ 58.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Novel mechanisms linking blood coagulation to liver fibrosis
将凝血与肝纤维化联系起来的新机制
  • 批准号:
    10452687
  • 财政年份:
    2021
  • 资助金额:
    $ 58.56万
  • 项目类别:
SBIR Phase II: CoagCare-A POC Blood Coagulation Diagnostic Platform That Utilizes A Hand-held Meter and Mechanically Sensitive Test Strips for Broad Spectrum Hemostasis Monitoring
SBIR II 期:CoagCare - POC 凝血诊断平台,利用手持式仪表和机械敏感试纸条进行广谱止血监测
  • 批准号:
    2050272
  • 财政年份:
    2021
  • 资助金额:
    $ 58.56万
  • 项目类别:
    Cooperative Agreement
Novel mechanisms linking blood coagulation to liver fibrosis
将凝血与肝纤维化联系起来的新机制
  • 批准号:
    10283268
  • 财政年份:
    2021
  • 资助金额:
    $ 58.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了